Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Calyculin A (HB0161)
Description:Potent, selective protein phosphatase 1 / 2A inhibitor
Purity:>98%
Cyclosporin A (HB0220)
Description:Potent calcineurin inhibitor. Inhibits MPTP opening.
Purity:>99%
Cyclosporin D (HB3860)
Description:Calcineurin inhibitor. Potent inhibitor of tumor promoting phorbol ester (TPA/PMA) effects.
Purity:>97%
FK 506 (HB0289)
Description:Potent calcineurin phosphatase 2B inhibitor. Enhances osteoblastic differentiation in mesenchymal cells.
Purity:>99%